• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与其他病因相比,遗传性肾病患者住院的可能性更高,费用也更高。

Genetic kidney disease has a higher likelihood and cost of inpatient admissions compared to other aetiologies.

作者信息

Sowa P Marcin, Mallett Andrew J, Connelly Luke B

机构信息

Centre for the Business and Economics of Health, The University of Queensland, St Lucia, Queensland, Australia.

NHMRC Chronic Kidney Disease Centre of Research Excellence, The University of Queensland, Herston, Queensland, Australia.

出版信息

Genet Med Open. 2024 Jul 25;2:101876. doi: 10.1016/j.gimo.2024.101876. eCollection 2024.

DOI:10.1016/j.gimo.2024.101876
PMID:39669631
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11613861/
Abstract

PURPOSE

There is increasing recognition of monogenic aetiologies for kidney disease. We sought to identify whether genetic kidney disease (GKD) has distinct hospitalization patterns compared to other forms of chronic kidney disease (CKD).

METHODS

Health service utilization analysis was undertaken in a CKD cohort study across public hospital services in Queensland, Australia. CKD due to clinically coded potential monogenic causes was compared to all other causes in terms of annual frequency, cost, and type of hospital admission.

RESULTS

We analyzed 7 years of hospital admissions data (809,188 admissions) among 29,046 patients. Compared to non-genetic CKD, GKD was associated with a higher likelihood and cost of admissions. GKD had consistently more admissions (mean excess annual number of admissions increasing from 5.2 in year 1 to 13.4 in year 7) and more costly admissions (mean excess annual cost increasing from $5,265 in year 1 to $12,993 in year 7). This gap in hospitalization likelihood and cost increased over time for both surgical and medical admission episodes, but not for all (immunological, cancer) causes of admissions.

CONCLUSION

Understanding the nature and extent of differences in healthcare needs between GKD and other CKD will enable better secondary prevention and inform resource allocation decisions to reduce healthcare system pressures attributable to knowable causes.

摘要

目的

人们对肾脏疾病的单基因病因的认识日益增加。我们试图确定与其他形式的慢性肾脏病(CKD)相比,遗传性肾脏病(GKD)是否具有独特的住院模式。

方法

在澳大利亚昆士兰州公立医院服务的一项CKD队列研究中进行了卫生服务利用分析。将临床编码的潜在单基因病因导致的CKD与所有其他病因在年度发生率、费用和住院类型方面进行比较。

结果

我们分析了29,046例患者7年的住院数据(809,188次住院)。与非遗传性CKD相比,GKD与更高的住院可能性和费用相关。GKD的住院次数一直更多(每年平均额外住院次数从第1年的5.2次增加到第7年的13.4次),住院费用也更高(每年平均额外费用从第1年的5265美元增加到第7年的12993美元)。手术和内科住院病例的住院可能性和费用差距随时间增加,但并非所有(免疫、癌症)住院病因都是如此。

结论

了解GKD和其他CKD在医疗需求方面差异的性质和程度,将有助于更好地进行二级预防,并为资源分配决策提供信息,以减轻可归因于已知病因的医疗系统压力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/11613861/9c823679a47e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/11613861/b83f4e298883/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/11613861/9c823679a47e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/11613861/b83f4e298883/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2abc/11613861/9c823679a47e/gr1.jpg

相似文献

1
Genetic kidney disease has a higher likelihood and cost of inpatient admissions compared to other aetiologies.与其他病因相比,遗传性肾病患者住院的可能性更高,费用也更高。
Genet Med Open. 2024 Jul 25;2:101876. doi: 10.1016/j.gimo.2024.101876. eCollection 2024.
2
Hospitalizations Among Adults With CKD in Public Renal Specialty Practices: A Retrospective Study From Queensland, Australia.澳大利亚昆士兰公立肾脏专科诊所中慢性肾脏病成年患者的住院情况:一项回顾性研究
Kidney Med. 2023 Jul 26;5(9):100700. doi: 10.1016/j.xkme.2023.100700. eCollection 2023 Sep.
3
Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.美国与常染色体显性多囊肾病相关的医院住院患者资源利用情况。
J Med Econ. 2015 Apr;18(4):303-11. doi: 10.3111/13696998.2014.985381. Epub 2015 Jan 20.
4
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study.达格列净治疗慢性肾脏病患者的短期成本:一项回顾性队列研究。
Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(9):1057-1066. doi: 10.1080/14737167.2023.2237679. Epub 2023 Aug 4.
5
Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.在美国大型行政索赔数据库中,新诊断为慢性肾脏病的 2 型糖尿病患者的年度医疗资源利用情况和成本。
J Manag Care Spec Pharm. 2020 Dec;26(12):1506-1516. doi: 10.18553/jmcp.2020.26.12.1506.
6
Costs and healthcare use of patients with chronic kidney disease in the Northern Territory, Australia.澳大利亚北领地慢性肾脏病患者的成本和医疗保健利用情况。
BMC Health Serv Res. 2024 Jul 9;24(1):791. doi: 10.1186/s12913-024-11258-8.
7
Incident gout and chronic Kidney Disease: healthcare utilization and survival.新发痛风与慢性肾脏病:医疗利用与生存情况
BMC Rheumatol. 2019 Mar 19;3:11. doi: 10.1186/s41927-019-0060-0. eCollection 2019.
8
Inequalities in emergency care use across transition from paediatric to adult care: a retrospective cohort study of young people with chronic kidney disease in England.从儿科到成人医疗过渡中急诊护理使用的不平等:英格兰慢性肾脏病年轻人的回顾性队列研究。
Eur J Pediatr. 2024 Jul;183(7):3105-3115. doi: 10.1007/s00431-024-05561-z. Epub 2024 Apr 26.
9
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?慢性肾脏病分期和心血管疾病对中重度肾脏病患者年度住院费用有何影响?
BMC Nephrol. 2015 Apr 29;16:65. doi: 10.1186/s12882-015-0054-0.
10
Identification of factors associated with high-cost use of inpatient care in chronic kidney disease: a registry study.识别与慢性肾脏病住院患者高费用使用相关的因素:一项注册研究。
BMJ Open. 2021 Aug 19;11(8):e049755. doi: 10.1136/bmjopen-2021-049755.

本文引用的文献

1
Genetic Testing for Chronic Kidney Diseases: Clinical Utility and Barriers Perceived by Nephrologists.慢性肾脏病的基因检测:肾脏病学家所认识到的临床效用及障碍
Kidney Med. 2021 Oct 5;3(6):1050-1056. doi: 10.1016/j.xkme.2021.08.006. eCollection 2021 Nov-Dec.
2
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理指南执行摘要。
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
3
Identification of factors associated with high-cost use of inpatient care in chronic kidney disease: a registry study.
识别与慢性肾脏病住院患者高费用使用相关的因素:一项注册研究。
BMJ Open. 2021 Aug 19;11(8):e049755. doi: 10.1136/bmjopen-2021-049755.
4
Do remote dialysis services really cost more? An economic analysis of hospital and dialysis modality costs associated with dialysis services in urban, rural and remote settings.远程透析服务真的更贵吗?对城市、农村和偏远地区透析服务相关的医院和透析模式成本的经济分析。
BMC Health Serv Res. 2021 Jun 17;21(1):582. doi: 10.1186/s12913-021-06612-z.
5
Costs and healthcare utilisation of patients with chronic kidney disease in Spain.西班牙慢性肾脏病患者的成本和医疗保健利用情况。
BMC Health Serv Res. 2021 Jun 1;21(1):536. doi: 10.1186/s12913-021-06566-2.
6
Clinical versus research genomics in kidney disease.肾脏病中的临床基因组学与研究基因组学
Nat Rev Nephrol. 2021 Sep;17(9):570-571. doi: 10.1038/s41581-021-00436-0.
7
The Preventable Productivity Burden of Kidney Disease in Australia.澳大利亚肾脏疾病可预防的生产力负担
J Am Soc Nephrol. 2021 Apr;32(4):938-949. doi: 10.1681/ASN.2020081148. Epub 2021 Mar 9.
8
Australia and New Zealand renal gene panel testing in routine clinical practice of 542 families.澳大利亚和新西兰542个家庭常规临床实践中的肾脏基因检测面板测试。
NPJ Genom Med. 2021 Mar 4;6(1):20. doi: 10.1038/s41525-021-00184-x.
9
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.KDIGO 2021慢性肾脏病血压管理临床实践指南执行摘要。
Kidney Int. 2021 Mar;99(3):559-569. doi: 10.1016/j.kint.2020.10.026.
10
Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics.澳大利亚肾脏病学家对临床基因组学实施的态度与实践
Kidney Int Rep. 2020 Nov 10;6(2):272-283. doi: 10.1016/j.ekir.2020.10.030. eCollection 2021 Feb.